The cost of COPD exacerbations: A university hospital – based study in Greece

Geitona, Mary; Latsou, Dimitra; Steiropoulos, Paschalis; Alexopoulos, Evangelos C.; Bouros, Demosthenes

doi:10.1016/j.rmed.2010.09.020

Cited by 48 publications

(44 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Another phenomenon is the challenge of changing prescribed drugs to generics, otherwise patients have to bear the cost on their own [13,87,95,102,105]. Hence, serious adverse events lead to higher costs due to disease complications [13,106,107]. However, MITSIKI et al [35] have reported that newly diagnosed COPD cases present a better compliance to treatment than the known COPD group.…”

Section: Treatment Adherence During Crisismentioning

confidence: 99%

“…Currently, it has been supported that about half of COPD exacerbations constitute severe exacerbations [13,106], which poses a significant economic burden on society. More specifically, nowadays it is estimated that per severe exacerbation €1711 will be spent and only €621 will be reimbursed by social security funds [106]. Additionally, the cost has been shown to increase in a linear fashion in the case of advanced disease (GOLD grades A-D) [41,106].…”

Section: Economic Burden Of Copd Exacerbations During the Greek Crisismentioning

confidence: 99%

“…More specifically, nowadays it is estimated that per severe exacerbation €1711 will be spent and only €621 will be reimbursed by social security funds [106]. Additionally, the cost has been shown to increase in a linear fashion in the case of advanced disease (GOLD grades A-D) [41,106]. Recently it was estimated that the mean cost of an exacerbation for Stage IV patients is approximately €2600, while for patients at Stages I, II and III it is approximately €1400 [99,106,107].…”

Section: Economic Burden Of Copd Exacerbations During the Greek Crisismentioning

confidence: 99%

“…Additionally, the cost has been shown to increase in a linear fashion in the case of advanced disease (GOLD grades A-D) [41,106]. Recently it was estimated that the mean cost of an exacerbation for Stage IV patients is approximately €2600, while for patients at Stages I, II and III it is approximately €1400 [99,106,107]. Combination therapies, as well as the cost of comorbidity-associated management, are the reasons for the large increase in medication expense in this group of patients [106,107].…”

Section: Economic Burden Of Copd Exacerbations During the Greek Crisismentioning

confidence: 99%

“…Recently it was estimated that the mean cost of an exacerbation for Stage IV patients is approximately €2600, while for patients at Stages I, II and III it is approximately €1400 [99,106,107]. Combination therapies, as well as the cost of comorbidity-associated management, are the reasons for the large increase in medication expense in this group of patients [106,107]. Another study estimated the annual per-patient direct costs (including the cost of exacerbations, hospitalisation and pharmaceutical treatment) of COPD to be €2810, 54% of which reflected the management of exacerbations [109].…”

Section: Economic Burden Of Copd Exacerbations During the Greek Crisismentioning

confidence: 99%

See 4 more Smart Citations

Impact of the financial crisis on COPD burden: Greece as a case study

et al. 2018

View full text Add to dashboard Cite

Poverty and low socioeconomic status have been associated with chronic obstructive pulmonary disease (COPD). The current financial crisis has forced millions back into poverty. Greece is one of the countries hit the hardest, and is in the middle of a deep ongoing collapse. There have been early reports stating the apparent effects of the Greek downturn on respiratory health. This review summarises the overall impact of the financial crisis on COPD burden throughout the period of economic downturn by analysing the case study of Greece. In all levels of the healthcare system, current economic restrictions have reduced the capacity to prevent, diagnose and treat COPD in parallel with current higher detection rates of COPD. Remarkably, expenditure on healthcare has been reduced by >25%, resulting in major healthcare equipment shortages. Lower wages (by up to 20%) and higher co-payments of up to 25% of a drug's purchase price have led to patients struggling to afford inhaled medications. Treatment nonadherence has been reported, resulting in 11.5% more exacerbations and 14.1% more hospitalisations annually, while the mean cost per severe COPD exacerbation has been approximated as €2600. Greece is a noteworthy example illustrating how COPD burden, quality of care and patients' outcome can be affected by economic crisis.

show abstract